Monitoring M-Protein, Therapeutic Antibodies, and Polyclonal Antibodies in a Multiparametric Mass Spectrometry Assay Provides Insight into Therapy Response Kinetics in Patients with Multiple Myeloma

Monitoring M-Protein, Therapeutic Antibodies, and Polyclonal Antibodies in a Multiparametric Mass Spectrometry Assay Provides Insight into Therapy Response Kinetics in Patients with Multiple Myeloma

<b>Background/Objectives:</b> Multiple Myeloma (MM) is a hematologic malignancy caused by clonally expanded plasma cells that produce a monoclonal immunoglobulin (M-protein), a personalized biomarker. Recently, we developed an ultra-sensitive mass spectrometry method to quantify minimal...

Full description

Saved in:
Bibliographic Details
Main Authors: Charissa Wijnands, Peter G. A. Karel, Jolein Gloerich, Gad Armony, Anastasia Tzasta, Corrie M. de Kat Angelino, Luciano Di Stefano, Vincent Bonifay, Theo M. Luider, Martijn M. VanDuijn, Sandra J. Croockewit, Elizabeth A. de Kort, Daan A. R. Castelijn, Claudia A. M. Stege, Hans J. C. T. Wessels, Alain J. van Gool, Niels W. C. J. van de Donk, Joannes F. M. Jacobs
Format: Article
Language:English
Published: MDPI AG 2025-01-01
Series:Pharmaceutics
Subjects:
multiple myeloma
therapeutic drug monitoring
minimal residual disease
therapy response kinetics
therapeutic antibody
bispecific antibody
Online Access:https://www.mdpi.com/1999-4923/17/1/135
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items